SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2013
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
35 Industrial Parkway, Branchburg, N.J. 08876
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Press Release Announcing Hydromer, Inc. Entering Into Two Medical Coating Licenses
Press Release Issued February 25, 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 26, 2013
/s/ Robert Y. Lee
Name: Robert Y. Lee
Title: Chief Financial Officer
Contact: Martin von Dyck
Executive Vice President
35 Industrial Parkway
Branchburg, NJ. USA
Phone 908 722 5000
Hydromer Enters Into Medical Coating Licenses with
Two International Medical Device Companies
Branchburg, February 25, 2013, --- Hydromer, Inc. (HYDI.PK) announced that during last 30 days it entered into License Agreements with two non-USA based medical device manufacturers.
In January 2013, an Agreement was entered with a Chinese Medical Device company licensing the use of a proprietary Hydromer® medical coating for use on Nelaton Urinary Self-Catheters. The Chinese Medical Device company intends to manufacture the catheters in China and sell the coated product globally.
In early February 2013, an Agreement was entered with a United Arab Emirates based Medical Device company licensing the use of two proprietary Hydromer® medical coatings for use on PTCA/PTA Catheters. This UAE based Medical Device company intends to market their precision vascular access catheters in the Middle East and Global markets.
“Our focus in the lucrative and rapidly growing Chinese Medical Device market is gaining momentum as more Chinese companies are evaluating our coatings which have previous approvals with international regulatory agencies such as the US FDA, SFDA, CE/ISO, Japanese and others.”, commented Martin von Dyck, Executive Vice President of Hydromer, Inc., adding, “We are quite proud with our new UAE relationship, who selected Hydromer coatings based on our superior performance, previous regulatory approvals and high certainty of preventing particulate contamination in the blood stream. Hydromer coatings continually pass the USP 788 Particulate Matter in Injections test and the challenging Japanese Ministry of Health’s Eluate test as well as the stringent ISO 8536-4 and China’s GB/T14233.1 tests for reducing oxidizable matter. Passing all of these required tests ensures that Hydromer medical coatings continue to be prized globally as a premium biocompatible value added product.”
About Hydromer, Inc.: Hydromer, Inc. is a bio-technology-based company involved in the research and development, manufacture, contract coating and commercialization of specialized polymer and hydrogel products for medical device, animal health, cosmetic, personal care, and industrial uses. These technologies include Hydromer lubricious / anti-microbial / anti-thrombogenic / cell anti-mitosis / cell growth enhancing coatings for the medical marketplace.
For additional information please visit the following Web-sites:
Hydromer ® is a registered trademark of Hydromer, Inc.